Keros Therapeutics KROS
NASDAQ KROS
$11.18 -0.22 (-1.93%)
At close: Oct 21, 2026 · 4:00 PM EDT

Keros Therapeutics (KROS) Capital Expenditures (2019 - 2025)

Updated

Keros Therapeutics' Capital Expenditures came in at $134,000 for Q4 2025, down 53.6% from $289,000 a year earlier but up 1.5% from the prior quarter.

Analysis

Keros Therapeutics (KROS) Capital Expenditures (2019 - 2025) Analysis & Trends

For FY2025, Keros Therapeutics' Capital Expenditures was $1.55 million, down 19.7% from FY2024.

  • Capital Expenditures carries a five-year compound annual growth rate of 39.5% (FY2020 to FY2025).
  • Going back by year, Capital Expenditures was $1.93 million in FY2024 (-21.6%), $2.46 million in FY2023 (+98.5%), $1.24 million in FY2022 (+21.2%) and $1.02 million in FY2021 (+248.3%).
  • The five-year range for quarterly Capital Expenditures is $132,000 (Q3 2025) to $1.06 million (Q1 2023).
  • Year-over-year, Capital Expenditures increased in 1 of the last eight quarters, with an average decline of 14.4%.
  • The fastest year-over-year change in Capital Expenditures over five years came in Q1 2023 (growth of 622.4%), and the weakest in Q3 2025 (a decline of 65.8%).
  • Business Quant data shows KROS's Capital Expenditures at $132,000 (Q3 2025), $720,000 (Q2 2025) and $565,000 (Q1 2025) in the three quarters before Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 2.93 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 1.32 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 322.00 Mn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 893.00 Mn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 321.00 Mn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 1.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 513.00 Mn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 140.00 Mn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 533.00 Mn
10 Keros Therapeutics 221.17 Mn -1.71 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 134,000.00
Sep 30, 2025 132,000.00
Jun 30, 2025 720,000.00
Mar 31, 2025 565,000.00
Dec 31, 2024 289,000.00
Sep 30, 2024 386,000.00
Jun 30, 2024 310,000.00
Mar 31, 2024 946,000.00
Dec 31, 2023 541,000.00
Sep 30, 2023 550,000.00
Jun 30, 2023 311,000.00
Mar 31, 2023 1.06 Mn
Dec 31, 2022 351,000.00
Sep 30, 2022 176,000.00
Jun 30, 2022 567,000.00
Mar 31, 2022 147,000.00
Dec 31, 2021 159,000.00
Sep 30, 2021 145,000.00
Jun 30, 2021 510,000.00
Mar 31, 2021 210,000.00
API Access

Keros Therapeutics Capital Expenditures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-expenditures&ticker=KROS&period=max&api_key=YOUR_API_KEY